CA2904523C - Methods of treating, reducing the incidence of, and/or preventing ischemic events - Google Patents

Methods of treating, reducing the incidence of, and/or preventing ischemic events Download PDF

Info

Publication number
CA2904523C
CA2904523C CA2904523A CA2904523A CA2904523C CA 2904523 C CA2904523 C CA 2904523C CA 2904523 A CA2904523 A CA 2904523A CA 2904523 A CA2904523 A CA 2904523A CA 2904523 C CA2904523 C CA 2904523C
Authority
CA
Canada
Prior art keywords
cangrelor
ticagrelor
pci
oral
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2904523A
Other languages
English (en)
French (fr)
Other versions
CA2904523A1 (en
Inventor
Clive Arthur Arculus-Meanwell
Simona Skerjanec
Jayne Prats
David J. Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CA2904523A1 publication Critical patent/CA2904523A1/en
Application granted granted Critical
Publication of CA2904523C publication Critical patent/CA2904523C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2904523A 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events Active CA2904523C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US13/792,056 2013-03-09
US201361815735P 2013-04-25 2013-04-25
US61/815,735 2013-04-25
PCT/US2013/043136 WO2014143107A1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Publications (2)

Publication Number Publication Date
CA2904523A1 CA2904523A1 (en) 2014-09-18
CA2904523C true CA2904523C (en) 2024-01-09

Family

ID=51537409

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2904523A Active CA2904523C (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Country Status (10)

Country Link
EP (2) EP3978002A1 (https=)
JP (3) JP6247708B2 (https=)
CN (2) CN115120606A (https=)
AU (1) AU2013381855B2 (https=)
BR (1) BR112015022070B1 (https=)
CA (1) CA2904523C (https=)
EA (1) EA034550B1 (https=)
ES (1) ES2904256T3 (https=)
PL (1) PL2964233T3 (https=)
WO (1) WO2014143107A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022070B1 (pt) * 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
US11260071B2 (en) 2017-06-23 2022-03-01 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281309B6 (sk) 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
RU2011132125A (ru) * 2008-12-30 2013-02-10 Тромбологик Апс Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения
EP2443120B1 (en) * 2009-06-16 2016-11-02 RSPR Pharma AB Crystalline form of pemirolast
PT2498731T (pt) * 2009-11-11 2020-02-21 Chiesi Farm Spa Métodos de tratamento ou prevenção de uma trombose de endoprótese
BR112015022070B1 (pt) * 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor

Also Published As

Publication number Publication date
ES2904256T3 (es) 2022-04-04
JP2016510738A (ja) 2016-04-11
CN115120606A (zh) 2022-09-30
EA034550B1 (ru) 2020-02-19
EP3978002A1 (en) 2022-04-06
BR112015022070A2 (pt) 2017-07-18
AU2013381855A1 (en) 2015-10-22
PL2964233T3 (pl) 2022-04-25
CA2904523A1 (en) 2014-09-18
EP2964233A4 (en) 2016-10-19
BR112015022070B1 (pt) 2022-01-18
EA201591683A1 (ru) 2016-08-31
EP2964233B1 (en) 2021-12-15
EP2964233A1 (en) 2016-01-13
WO2014143107A1 (en) 2014-09-18
JP6247708B2 (ja) 2017-12-13
JP2019178177A (ja) 2019-10-17
CN106102750A (zh) 2016-11-09
JP2018002739A (ja) 2018-01-11
AU2013381855B2 (en) 2018-08-02
JP6840197B2 (ja) 2021-03-10

Similar Documents

Publication Publication Date Title
US11351187B2 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20230210880A1 (en) Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events
US8680052B1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20250228948A1 (en) Methods of treating or preventing stent thrombosis
Leonardi et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial
CA2904523C (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US9492437B2 (en) Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients
WO2014142780A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
MX2011005376A (es) Metodo para reducir trombocitopenia y mortalidad asociada a trombocitopenia.
WO2015054542A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
KR20260035128A (ko) 심혈관 또는 뇌혈관 질환을 갖는 환자에서의 혈전성 상태의 치료 및 예방에서의 밀벡시안의 용도
TW202241446A (zh) 治療方法
TW200409638A (en) Use of MELOXICAM in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180228

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523